\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Characteristic Features of the Content of Natural IgG Class Autoantibodies to Nervous Tissue Proteins in Neuroaids},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2019-01-15 (revised: 15 January 2019)}
\def\TheID{\makeatother }
\def\TheDate{2019-01-15}
\title{Characteristic Features of the Content of Natural IgG Class Autoantibodies to Nervous Tissue Proteins in Neuroaids}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Bekhzod  Abdullaev}

             \author[2]{Satima R.  Kuranbaeva}

\renewcommand\Authands{ and }

\date{\small \em Received: 16 December 2018 Accepted: 4 January 2019 Published: 15 January 2019}

\maketitle


\begin{abstract}
        


An increase in immunoreactivity is revealed, which is represented by a change in the level of neurotropic autoantibodies to neurotransmitter proteins involved in pathogenesis and formation of aberrant plasticity in patients with HIV infection. The increase in the content of autoantibodies to neurospecific proteins causes the onset, progression and preservation of pathological process depending on the presence of disorders in the nervous system.

\end{abstract}


\keywords{HIV, pathogenesis, immune reactivity.}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
ccording to UNAIDS, about 50 million people are HIV-infected on the planet. People (less than 10\% know about their illness) 16 million already died of AIDS. HIV infection is registered in152 countries of the world. More than 60000 newly diagnosed HIV carriers are registered on a monthly basis in the world, every 4 minutes a new AIDS patient, every 15 seconds a new infected HIV  {\ref [1, 3 and 6]}. It is known that neurospecific antibodies to hippocampus and other neuronal structures contribute to the implementation of the launch and further maintenance of the generator pathologically intensified excitation and hence the development of neurological complications with HIV \hyperref[b3]{[4,}\hyperref[b4]{5]}. 
\section[{The purpose of the study:}]{The purpose of the study:}\par
To establish the role of natural autoantibody (AAB) class IgG to nerve tissue proteins (S-100, GFAP, NF-200 and Main Protein of Myelin (MPM)) in the pathogenesis of the nervous system lesions in HIV. 
\section[{II.}]{II.} 
\section[{Materials and Methods}]{Materials and Methods}\par
The level of autoantibodies to neurotropic proteins was determined in the blood serum of 99 patients with HIV Infection. The average age of patients was 38,9±1,2 years, of them 44,4 \% (44) were women, 55,6\% (55) were men. In the course of the study, 4 groups of the patients were identified: defeats of the neurosystem, conditionally not connected with HIV and caused by stress, toxic-allergic influence, presence of somatic pathology and other factors (48 patients, 48.5\%; 1 st group); with the primary lesion of nervous the blood and symptoms of lesions of other organs and systems, but concurrent with the violation of immunologic constants (primary neuroAIDS S-9.1\% (9 patients); 2 nd group); With the secondary lesion of the nervous system as a manifestation of intensified opportunistic infection and progressed expressed immunodeficiency (secondary neuroAIDS-22, 2 \% (22 patients); 3 rd group); Patients without lesions of the nervous system (20 patients, 20.2\%; 4 th group). A quantitative definition of serum immune reactivity antibodies (AB1 and AB2) to the receptors of neurotransmitters was carried out with the help of solid Immunoassay method ELI-N-Test and the same name test-sets, production of "MITS Immunkulus" (Russia). 20 clinically healthy people, comparable in sex and age were monitored. 
\section[{III.}]{III.} 
\section[{Results}]{Results}\par
In clinically healthy people (control group), the defined indices were as follows: AAB S100-77.5±7.6 y.e., AAB GFAP -57.9±5.7 y.e., AAB NF-200-72.9±7.1 y.e, AAB MPM-58.8±5.6 y.e. When evaluating the results of immunological research it was established that all groups of patients differed from the control group, both in level and in the degree of dispersion of studied immunological indices. And the nature of immune disorders directly depended on the presence of lesions of the nervous system. So, the highest among the studied AAT in all groups was the level of AAB to S100 and in patients with the defeat of the nervous system against the background of HIV, this figure exceeded the normative values on average 1.9 times (p < 0.01), and in patients without the defeat of the neurosystem 1.6 times (p < 0.05 ). Such a significant increase in the level of AAB to the protein S100, which is a calcium-binding protein, can be a confirmation of the hypothesis that one of the links of the pathogenesis of lesions of the neurosystem with HIV is to increase the permeability of neural membranes for ions Ca 2+ with the increase of their concentration in the intercellular space. It should be noted that AAB to the protein S100, Depolarized the membrane of the neuron, change its potential (table1).\par
The level of whey autoantibodies to neurotropic proteins in patients with symptomatic and idiopathic epilepsy, y.e.  Given the fact that the soluble Ca-binding protein neural tissue S100 is a trophic factor for Serotoninergic neurons, regulates the permeability of ion channels the detection of autoantibodies in this protein has a great clinical value in neurological practice and can be used as a marker for brain tissue damage in patients with HIV. Analysis of the level of AAB to the protein NF200 also showed a reliable increase in their titles in patients in all groups, including patients without defeating the NS against the background of HIV (on average 1.7 times with the defeat of the NS and 1.3 times without defeat, respectively, p<0.05). At the same time there was a reliable prevalence of the level of AAB to NF200 in patients with non-defeated NS (101.8±6.2 y.e. against 72.9±7.1 y.e, p<0.05),which indicates the excess plasticity, which is likely to preserve more durable pathological connections of the neurological system in patients with HIV.The level of whey AAB to Neurospecific protein MPM also reliably exceeded the values of the control group in all groups on average 1.7 times in patients with the defeat of the NS, (p<0.01) and 1.3 times in patients without defeat NS, respectively, (p<0.05). It is known, that myelin possesses the expressed immunogenic property, and its destruction is the universal mechanism of reaction of nervous tissue on various damages. The emergence of elevated indices of antibodies to MPM in the blood serum indicates a violation of the brain barrier, the most significant in patients without defeating the NS against the background of HIV. It should be noted that GFAP plays fundamental role in maintaining the normal functioning of both individual astrocytes and CNS as a whole. The change of its content has an important clinical value in diseases of the Nervous System. In patients with HIV, both with the defeat of the NS and without defeat a reliable increase in the group with the defeat of the NS on average 1.8 times was established, and without hitting the NS 1.6 times (p<0.05). 
\section[{IV.}]{IV.} 
\section[{Conclusion}]{Conclusion}\par
Thus, the clinical-immunological analysis revealed a clear regularity of the content of antibodies to neurotropic proteins depending on the presence of the NS lesion in HIV, which evidence of the worsening of neuroimmune irregularities as increase in the level of defeat of the NS in patients with HIV. \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.40605095541401276\textwidth}P{0.07850318471337579\textwidth}P{0.07579617834394904\textwidth}P{0.07714968152866242\textwidth}P{0.1502388535031847\textwidth}P{0.06226114649681528\textwidth}}
Indicators\tabcellsep 1 st group (n=48)\tabcellsep 2 nd group(n=9)\tabcellsep 3 rd group (n=22)\tabcellsep 4 th group (n=20)\tabcellsep Control (n=20)\\
NF200\tabcellsep 127,6±8,9*\tabcellsep 137,6±6,9*\tabcellsep 121,8±8,2*\tabcellsep 101,8±6,2\textasciicircum ?\tabcellsep 72,9±7,1\\
GFAP\tabcellsep 100,4±7,2*\tabcellsep 118,4±5,2*\tabcellsep 102,5±8,3*\tabcellsep 92,5±7,3?\tabcellsep 57,9±5,7\\
S100\tabcellsep 130,3±11,8*\tabcellsep 150,3±11,8*\tabcellsep 124,1±4,6*\tabcellsep 104,1±5,6\textasciicircum ?\#\tabcellsep 77,5±7,6\\
MPM\tabcellsep 118,8±7,7*\tabcellsep 119,6±6,7*\tabcellsep 102,4±8,0*\tabcellsep 82,4±5,0*\textasciicircum ?\#\tabcellsep 58,8±5,5\\
\multicolumn{6}{l}{Note: *-reliability of data in relation to the control group (p<0.05-0.001; \textasciicircum  reliability of data in relation to 1st group (p < 0.05);}\\
\multicolumn{6}{l}{A -reliability of data on the relation to the second group (p<0.05); \# -data reliability in relation to 3rd groups (p<0.05)}\end{longtable} \par
 
\caption{\label{tab_0}Table 1}\end{figure}
 			\footnote{( )K © 2019 Global Journals} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Krijanovski et al. ()]{b3}\label{b3} 	 		\textit{},  		 			G N Krijanovski 		,  		 			S V Magaeva 		,  		 			S V Makarov 		,  		 			R I Sepiashvili 		,  		 			Neuroimmunopathology 		.  		2003. 438 p. p.  	 
\bibitem[Hiv Infection et al. ()]{b2}\label{b2} 	 		\textit{// Information bulletin},  		 			/ V V Hiv Infection 		,  		 			N N Pokrovsky 		,  		 			E V Ladnaya 		,  		 			Sokolova 		.  		2005. p. .  	 
\bibitem[Butylsky ()]{b0}\label{b0} 	 		‘Dynamics of immunity parameters in patients at different stages of HIV infection’.  		 			A N Butylsky 		.  	 	 		\textit{Immunology}  		/ A.N. Butylsky, B.I. Kuznik (ed.)  		2005.  (2-3)  p. .  	 
\bibitem[How to reverse the epidemic. State of the Problem and Possible Solutions HIV/AIDS in Eastern Europe and the Commonwealth of Independent States ()]{b1}\label{b1} 	 		‘How to reverse the epidemic. State of the Problem and Possible Solutions’.  	 	 		\textit{HIV/AIDS in Eastern Europe and the Commonwealth of Independent States},  				2004. p. .  	 
\bibitem[Poletaev et al. ()]{b4}\label{b4} 	 		\textit{Natural neurotropic autoantibodies and pathology of the nervous system},  		 			A B Poletaev 		,  		 			V V Alferova 		,  		 			A A Abrosimova 		,  		 			I A Komissarova 		,  		 			M A Sokolov 		,  		 			E I Gusev 		.  		2003. p. .  	 
\bibitem[Bartt ()]{b5}\label{b5} 	 		\textit{The Neurology of AIDS // JAMA},  		 			R E Bartt 		.  		2006. 295.  	 	 (331 p) 
\end{bibitemlist}
 			 		 	 
\end{document}
